{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:54:42Z","timestamp":1789048482620,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICI) reinvigorate the immune system to recognize and destroy tumor cells. Because of this biological mechanism, patients might develop autoimmune toxicities, notably in the digestive tract (most frequently, hepatitis or colitis). A 70-year-old man with relapsed mesothelioma was treated with nivolumab in 3rd line. He was hospitalized for watery and foul-smelling diarrhea. He underwent gastrointestinal endoscopy, showing duodenitis and villous atrophy and measurement of serum IgA antibodies to tissue transglutaminase (tTG-IgA+), leading to the diagnosis of ICI-induced celiac disease. He was treated with steroids, proton pump inhibitors, and a gluten-free diet. If ICI-induced celiac disease is rare in the literature, increasing reports suggest that celiac disease might represent an underestimated ICI toxicity. This case highlights the necessity of complementary investigation (including tTG-IgA and endoscopic biopsies) in patients with atypical digestive symptoms during immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2021.799666","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T06:41:11Z","timestamp":1639723271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Julie","family":"Leblanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solene","family":"Hoibian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Boucraut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Ratone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Stoffaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domitille","family":"Dano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Louvel-Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Chanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Chretien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Madroszyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rochigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1038\/s41424-018-0049-9","article-title":"Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis","volume":"9","author":"Reddy","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A Review of Cancer Immunotherapy Toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2011-301346","article-title":"The Oslo Definitions for Coeliac Disease and Related Terms","volume":"62","author":"Ludvigsson","year":"2013","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","first-page":"355.e9","DOI":"10.1016\/j.amjmed.2005.08.044","article-title":"Trends in the Presentation of Celiac Disease","volume":"119","author":"Rampertab","year":"2006","journal-title":"Am J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-019-1380-z","article-title":"Celiac Disease: A Comprehensive Current Review","volume":"17","author":"Caio","year":"2019","journal-title":"BMC Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.015","article-title":"Association Between Ipilimumab and Celiac Disease","volume":"88","author":"Gentile","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e15565","DOI":"10.7759\/cureus.15565","article-title":"Association of Celiac Disease With Pembrolizumab","volume":"13","author":"Sethi","year":"","journal-title":"Cureus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0694-x","article-title":"A Case of Checkpoint Inhibitor-Induced Celiac Disease","volume":"7","author":"Alsaadi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e00158","DOI":"10.14309\/crj.0000000000000158","article-title":"A Celiac Disease Phenotype After Checkpoint Inhibitor Exposure: An Example of Immune Dysregulation After Immunotherapy","volume":"6","author":"Arnouk","year":"2019","journal-title":"ACG Case Rep J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e000958","DOI":"10.1136\/jitc-2020-000958","article-title":"Immune Checkpoint Inhibitor-Associated Celiac Disease","volume":"8","author":"Badran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1586\/egh.11.38","article-title":"Clinical and Immunological Features of Celiac Disease in Patients With Type 1 Diabetes Mellitus","volume":"5","author":"Volta","year":"2011","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of Immune Checkpoint Inhibitors: A Histology Study of Seven Cases in Comparison With Autoimmune Hepatitis and Idiosyncratic Drug-Induced Liver Injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2018.14","article-title":"Gastrointestinal Toxicity of Immune Checkpoint Inhibitors: From Mechanisms to Management","volume":"15","author":"Samaan","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.799666\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T06:41:12Z","timestamp":1639723272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.799666\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2021.799666"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.799666","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"article-number":"799666"}}